Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442

S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba

Laboratory of Pharmaceuticals, Mitsubishi Kasei Corp., Yokohama, Japan.

In the search for 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives, we have found 6-benzyl-1-(ethoxymethyl)-5-isopropyl-uracil (MKC-442) to be a highly potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). The IC50 value of MKC-442 for HIV-1 RT was 8 nM. MKC-442 did not inhibit HIV-1 RNase H, other RTs, or DNA polymerase alpha. Because its inhibitory pattern showed noncompetitive inhibition with regard to nucleotide substrates, its mode of action was considered to be allosteric inhibition. From the results of combination studies, MKC-442 was found to produce synergistic inhibition of HIV-1 RT with 3'-azido- 2',3'-dideoxythymidine (AZT) 5'-triphosphate (AZT.TP). The dose of AZT.TP required for 50% inhibition was reduced to one tenth of control in the presence of a half dose of MKC-442. Although other allosteric inhibitors (Nevirapine, L-696,229, and R82,913) had the same specificity for enzyme inhibition, they did not show synergism with AZT.TP in the combination index and synergy plot analyses. Synergistic inhibition of HIV-1 replication by MKC-442 and AZT has also been observed in HIV-1-infected MT-4 cells. These results suggest that MKC- 442 is a unique inhibitor of HIV-1 RT, and combination therapy with MKC- 442 and AZT could be advantageous in the treatment of acquired immune deficiency syndrome.

Volume 44, Issue 4, pp. 895-900, 10/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				H. Akiyama, E. Ido, W. Akahata, T. Kuwata, T. Miura, and M. Hayami Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type 1 J. Gen. Virol., July 1, 2003; 84(7): 1663 - 1669. [Abstract] [Full Text] [PDF]

				G. Maga, U. Hübscher, M. Pregnolato, D. Ubiali, G. Gosselin, and S. Spadari Potentiation of Inhibition of Wild-Type and Mutant Human Immunodeficiency Virus Type 1 Reverse Transcriptases by Combinations of Nonnucleoside Inhibitors and D- and L-({beta})-Dideoxynucleoside Triphosphate Analogs Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1192 - 1200. [Abstract] [Full Text]

				G. M. Szczech, P. Furman, G. R. Painter, D. W. Barry, K. Borroto-Esoda, T. B. Grizzle, M. R. Blum, J.-P. Sommadossi, R. Endoh, T. Niwa, et al. Safety Assessment, In Vitro and In Vivo, and Pharmacokinetics of Emivirine, a Potent and Selective Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., January 1, 2000; 44(1): 123 - 130. [Abstract] [Full Text]